+

WO2001077107A8 - Production et utilisation de composes heterocycliques - Google Patents

Production et utilisation de composes heterocycliques

Info

Publication number
WO2001077107A8
WO2001077107A8 PCT/JP2001/002937 JP0102937W WO0177107A8 WO 2001077107 A8 WO2001077107 A8 WO 2001077107A8 JP 0102937 W JP0102937 W JP 0102937W WO 0177107 A8 WO0177107 A8 WO 0177107A8
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
oxazole derivatives
formula
alkyl
Prior art date
Application number
PCT/JP2001/002937
Other languages
English (en)
Other versions
WO2001077107B1 (fr
WO2001077107A1 (fr
Inventor
Akihiro Tasaka
Takenori Hitaka
Etsuya Matsutani
Original Assignee
Takeda Chemical Industries Ltd
Akihiro Tasaka
Takenori Hitaka
Etsuya Matsutani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15211501A priority Critical patent/IL152115A0/xx
Priority to US09/889,974 priority patent/US6716863B2/en
Priority to HU0300434A priority patent/HUP0300434A3/hu
Priority to SK1413-2002A priority patent/SK14132002A3/sk
Priority to CA002404760A priority patent/CA2404760A1/fr
Priority to EEP200200576A priority patent/EE200200576A/xx
Priority to PL01365787A priority patent/PL365787A1/xx
Priority to EP01917827A priority patent/EP1268473A1/fr
Priority to KR1020017011568A priority patent/KR20020028865A/ko
Priority to AU2001244726A priority patent/AU2001244726A1/en
Application filed by Takeda Chemical Industries Ltd, Akihiro Tasaka, Takenori Hitaka, Etsuya Matsutani filed Critical Takeda Chemical Industries Ltd
Priority to BR0109851-9A priority patent/BR0109851A/pt
Priority to MXPA02009621A priority patent/MXPA02009621A/es
Publication of WO2001077107A1 publication Critical patent/WO2001077107A1/fr
Publication of WO2001077107B1 publication Critical patent/WO2001077107B1/fr
Priority to NO20024742A priority patent/NO20024742L/no
Publication of WO2001077107A8 publication Critical patent/WO2001077107A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un composé, ou un de ses sels, représenté par la formule (1) dans laquelle m prend la valeur 1 ou 2, R1 représente un halogène ou un groupe alkyle en C¿1-2? éventuellement halogéné, l'un des R?2 et R3¿ représente un atome d'hydrogène et l'autre représente un groupe de formule (2) ou (3) dans laquelle n prend la valeur 3 ou 4, et R4 représente un groupe alkyle en C¿1-4? substitué par 1 ou 2 groupes hydroxy. Ce composé possède une activité inhibitrice de tyrosine kinase.
PCT/JP2001/002937 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques WO2001077107A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020017011568A KR20020028865A (ko) 2000-04-07 2001-04-05 복소환식 화합물, 그의 제조 및 용도
HU0300434A HUP0300434A3 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
SK1413-2002A SK14132002A3 (sk) 2000-04-07 2001-04-05 Deriváty oxazolu, spôsob ich výroby a použitia a farmaceutický prostriedok
CA002404760A CA2404760A1 (fr) 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques
EEP200200576A EE200200576A (et) 2000-04-07 2001-04-05 Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
PL01365787A PL365787A1 (en) 2000-04-07 2001-04-05 Heterocyclic compounds, their production and use
EP01917827A EP1268473A1 (fr) 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques
IL15211501A IL152115A0 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors
US09/889,974 US6716863B2 (en) 2000-04-07 2001-04-05 Heterocyclic compounds their production and use
AU2001244726A AU2001244726A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors
BR0109851-9A BR0109851A (pt) 2000-04-07 2001-04-05 Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
MXPA02009621A MXPA02009621A (es) 2000-04-07 2001-04-05 Derivados de oxazol y sus usos como inhibidores de tirosina cinasa.
NO20024742A NO20024742L (no) 2000-04-07 2002-10-02 Heterocykliske forbindelser, deres fremstilling og anvendelse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-106836 2000-04-07
JP2000106836 2000-04-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/889,974 A-371-Of-International US6716863B2 (en) 2000-04-07 2001-04-05 Heterocyclic compounds their production and use
US10/620,706 Division US20040024035A1 (en) 2000-04-07 2003-07-17 Heterocyclic compounds, their production and use

Publications (3)

Publication Number Publication Date
WO2001077107A1 WO2001077107A1 (fr) 2001-10-18
WO2001077107B1 WO2001077107B1 (fr) 2001-12-20
WO2001077107A8 true WO2001077107A8 (fr) 2003-02-13

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002937 WO2001077107A1 (fr) 2000-04-07 2001-04-05 Production et utilisation de composes heterocycliques

Country Status (19)

Country Link
US (2) US6716863B2 (fr)
EP (1) EP1268473A1 (fr)
KR (1) KR20020028865A (fr)
CN (1) CN1444582A (fr)
AU (1) AU2001244726A1 (fr)
BR (1) BR0109851A (fr)
CA (1) CA2404760A1 (fr)
CO (1) CO5261589A1 (fr)
CZ (1) CZ20023264A3 (fr)
EE (1) EE200200576A (fr)
HU (1) HUP0300434A3 (fr)
IL (1) IL152115A0 (fr)
MX (1) MXPA02009621A (fr)
NO (1) NO20024742L (fr)
OA (1) OA12244A (fr)
PE (1) PE20011178A1 (fr)
PL (1) PL365787A1 (fr)
SK (1) SK14132002A3 (fr)
WO (1) WO2001077107A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136079A4 (fr) * 1998-10-08 2004-09-22 Takeda Chemical Industries Ltd Agents destines a retarder le passage d'un cancer hormono-dependant a un cancer hormono-independant
AU2001271058A1 (en) * 2000-07-19 2002-01-30 Takeda Chemical Industries Ltd. Method for producing 1-substituted-1,2,3-triazole derivative
EP1382350A4 (fr) * 2001-04-25 2006-01-04 Takeda Pharmaceutical Remedes contre la recurrence postoperative du cancer du sein chez les femmes en premenopause
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2002087619A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
JP2003137814A (ja) * 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
EP1439178A4 (fr) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
AU2002349477A1 (en) * 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
EP1572083A4 (fr) 2002-04-25 2008-09-24 Univ Connecticut Health Ct Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal
CN100339078C (zh) * 2002-12-16 2007-09-26 橘生药品工业株式会社 固体口服剂型药物
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
AR044098A1 (es) 2003-04-30 2005-08-24 Hoffmann La Roche Derivados de anilina, su elaboracion, composiciones farmaceuticas y su uso para elaborar medicamentos para el tratamiento del cancer
US7247649B2 (en) 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200612914A (en) 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
RU2006138424A (ru) 2004-04-02 2008-05-10 Ф.Хоффманн-Ля Рош Аг (Ch) Новые производные диазина, их получение и применение в качестве фармацевтических агентов
US7005526B2 (en) 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) * 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
AR050944A1 (es) * 2004-09-22 2006-12-06 Hoffmann La Roche Derivados de indol, su fabricacion y su utilizacion como agentes farmaceuticos
AR050652A1 (es) * 2004-09-24 2006-11-08 Hoffmann La Roche Derivados de oxazol, preparacion y uso como inhibidores de la tirosina quinasa
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
TW200738680A (en) 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
JP2009504586A (ja) * 2005-08-08 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー ピラゾール誘導体、それらの製造及び医薬品としての使用
CN101233130A (zh) * 2005-09-30 2008-07-30 霍夫曼-拉罗奇有限公司 二嗪唑衍生物，它们的制备和作为药剂的应用
WO2008034579A1 (fr) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag Derives de 2-heterocyclyl-5-phenoxymethylpyridine utilises en tant qu'agents anticancereux
EP2103620A1 (fr) 2006-12-12 2009-09-23 Takeda Pharmaceutical Company Limited Composé hétérocyclique condensé
WO2008133102A1 (fr) 2007-04-20 2008-11-06 Daido Chemical Corporation Nouvelle base pour dispersion solide sèche, dispersion solide contenant la base et composition contenant la dispersion
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
TW201016704A (en) * 2008-09-26 2010-05-01 Takeda Pharmaceutical Prevention and treatment of cancer with RAS gene mutation
US9023398B2 (en) 2009-09-30 2015-05-05 Kabushiki Kaisha Sangi Method for improving the aqueous solubility of poorly-soluble substances
WO2011105534A1 (fr) 2010-02-26 2011-09-01 日新化成株式会社 Capsule dure et sa méthode de production
WO2011153050A1 (fr) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Méthodes et utilisation de composés qui se lient au complexe du récepteur her2/neu
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
JP6225113B2 (ja) 2012-09-26 2017-11-01 武田薬品工業株式会社 固体粒子の製造方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
EP3238711B1 (fr) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base pour dispersion solide, procédé de production d'une dispersion solide l'utilisant et dispersion solide
CA2995617A1 (fr) * 2017-11-03 2019-05-03 Universite De Montreal Inhibiteurs d'activite mitochondrique heterocycliques et utilisations associees
EP3806887A4 (fr) 2018-06-13 2022-04-06 California Institute of Technology Nanoparticules permettant de traverser la barrière hématoencéphalique et méthodes de traitement faisant appel à celle-ci
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97872A (en) 1990-04-16 1996-07-23 Rhone Poulenc Rorer Int Pharmaceutical compositions containing styryl-substituted monocylic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase and a compounds of this type
CN1077107C (zh) * 1996-07-19 2002-01-02 武田药品工业株式会社 杂环化合物、其制备和用途

Also Published As

Publication number Publication date
CZ20023264A3 (cs) 2003-02-12
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
WO2001077107B1 (fr) 2001-12-20
AU2001244726A1 (en) 2001-10-23
MXPA02009621A (es) 2003-05-14
CO5261589A1 (es) 2003-03-31
HUP0300434A3 (en) 2004-11-29
KR20020028865A (ko) 2002-04-17
EE200200576A (et) 2004-06-15
NO20024742D0 (no) 2002-10-02
CA2404760A1 (fr) 2001-10-18
HUP0300434A2 (hu) 2003-06-28
OA12244A (en) 2006-05-10
US6716863B2 (en) 2004-04-06
US20040024035A1 (en) 2004-02-05
CN1444582A (zh) 2003-09-24
US20020173526A1 (en) 2002-11-21
NO20024742L (no) 2002-11-25
IL152115A0 (en) 2003-05-29
BR0109851A (pt) 2003-06-03
SK14132002A3 (sk) 2003-04-01
WO2001077107A1 (fr) 2001-10-18
EP1268473A1 (fr) 2003-01-02

Similar Documents

Publication Publication Date Title
WO2001077107A8 (fr) Production et utilisation de composes heterocycliques
CO5280078A1 (es) Compuestos
YU17092A (sh) Derivati 2,4-diaminohinazolina
EP1288199A4 (fr) Inhibiteurs de mmp-12
EP0931788A3 (fr) Inhibiteurs de la métalloprotéinase
WO2002074726A3 (fr) Inhibiteurs de phosphodiesterase 4
CO5031285A1 (es) Triarilimidazoles
AU1180797A (en) Phenylimidazolidines and use thereof as an antiandrogenic agent
WO2001090071A3 (fr) Iminoazines substituees
MY104627A (en) A 1-pyridylimidazole derivative and its production and use.
EP1291344A4 (fr) Agents de controle de la piriculariose du riz
DK0862562T3 (da) Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
EP0908453A4 (fr)
EP0640586A4 (fr) Derive de stilbene et derive d'analogue de stilbene, et utilisation de ces derives.
WO2002024663A3 (fr) Composes pyrimidiques et leur utilisation
DK1086096T3 (da) Benzamider med tetrahydrofuranyloxy-substituenter som inhibitorer af phosphodiesterase 4
WO2002028844A1 (fr) Dérivés thiazole ou oxazole
WO2002000638A3 (fr) Nouveaux phthalides substitues, leur procede de preparation et compositions pharmaceutiques les contenant
ES2078876A1 (es) Una composicion herbicida a base de fenilpirazol 3-sustituidos.
AU2001269540A1 (en) Serotonin reuptake inhibitors
CA2412596A1 (fr) Inhibiteurs de phosphodiesterase specifique de gmp cyclique
WO2003072576A3 (fr) Composes chimiques
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
EP0757987A4 (fr) Derive de l'acide pyrazolecarboxylique et agent de lutte contre les maladies vegetales
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09889974

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020017011568

Country of ref document: KR

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009621

Country of ref document: MX

Ref document number: PV2002-3264

Country of ref document: CZ

Ref document number: 2404760

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14132002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 152115

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/02290

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 018077927

Country of ref document: CN

Ref document number: IN/PCT/2002/1267/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200208126

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 522224

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001917827

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001244726

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4984

Country of ref document: GE

Ref document number: 1200201010

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2002 2002129898

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001917827

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3264

Country of ref document: CZ

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWR Wipo information: refused in national office

Ref document number: PV2002-3264

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001917827

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载